NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC.T. SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., MBA., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA,AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
BACKGROUND

These sources critically examine the role of biased medical experts, particularly Dr. Timothy King, in opioid-related legal cases against doctors, suggesting their testimony has led to unjust prosecutions.
The authors argue that a lack of understanding regarding scientific limitations and the subjective nature of pain within the legal system contributes to these miscarriages of justice.

While seemingly overlooked, there is Thomas W. Prevoznik: DEA Deputy Assistant Administrator, Diversion Control Division. Author of letters to Dr.Richard Lawhern et al., clarifying the DEA’s position on prescribing controlled substances for pain, emphasizing the DEA’s limited authority in dictating medical practice or defining, “legitimate medical purpose,” which rests with individual practitioners.
- 1973: Eddie Mercury (of Queen) writes the lyrics to the song “Great King Rat,” which becomes a metaphor used to describe Dr. Timothy King. The Controlled Substances Act (CSA) is established in the U.S., creating a “Closed System of Distribution” for controlled substances.
- 1970s: The pharmacological understanding of opioid dependence (a physical reaction, not addiction) is well-established.
- Late 1990s: The article suggests the emergence of a “sinister alliance” between for-profit healthcare insurance corporations and unscrupulous physicians related to pain management and opiate prescription practices.
- 2006: The DEA publishes the “Practitioner’s Manual” to guide physicians on legitimate controlled substance prescribing and to curb “pill mill” practices.
- November 5, 2018: A provisional patent application (Ser. No. 62/755,605) is filed related to a forensic system for detecting fraud, abuse, and diversion of controlled substances.
- October 29, 2019: The full patent application (Appl. No. 16/666,971) for the “Forensic System and Method for Detecting Fraud, Abuse, and Diversion in the Prescriptive Use of Controlled Substances” is filed by Timothy Earl King.
- May 7, 2020: The U.S. Patent Application Publication US 2020/0143925 A1 for Dr. King’s forensic system is published.
- 2022: The U.S. CDC issues its Clinical Practice Guideline for pain management, which is later noted to not be a “consensus” standard and faces criticism from clinicians.
- October 26, 2023 (based on source publication date): The briefing document “THE GREAT KING RAT: UNCOVERING DOJ- DEA’s DR. TIMOTHY E. KING, MD TRAVELING SHOW OF LIES AND DECEPTIONS” is published on youarewithinthenorms.com, detailing allegations against Dr. Timothy King.
- September 12, 2023: Dan Martin JD publishes an article in Medical Economics mentioning the use of data analytics and AI by federal agencies for health care fraud detection, with a caution against using it as conclusive evidence.
- 2024 (Byrd’s analysis): William Byrd of the United States Institute of Peace (USIP) publishes analyses on the economic consequences of the Taliban’s opium ban in Afghanistan and the impact of reduced international aid.
- September 12, 2024: Richard A. Lawhern, PhD, publishes an article titled “How biased medical experts are destroying doctors’ lives and careers in the opioid crisis,” discussing the issues with expert witness testimony and the prosecution of doctors in the opioid crisis.

In the article on KevinMD.com, written by Dr. Richard A. Lawhern, Ph.D. argues that biased medical experts are unfairly prosecuting doctors in the opioid crisis. Lawhern, a patient advocate, contends that these “hired gun” experts often lack a true understanding of medical literature and its weaknesses, misleading judges and juries.
1841: Scottish journalist Charles Mackay publishes “Extraordinary Popular Delusions and the Madness of Crowds,” a work referenced in the context of widespread but potentially flawed beliefs.
2000s
- 1999-2001: Congress criticizes the DEA for a lack of progress against illegal drugs. The DOJ rebukes the DEA’s strategy, prompting a search for a new “front” in the War on Drugs.
- Early 2000s: Opioid prescriptions skyrocket, increasing addiction. “Pill mills” emerge.
- Early 2000s: Glen A. Fine, Inspector General of the Department of Justice, questions why the DEA isn’t doing more to combat prescription drug abuse.
- 2001: The DEA launches the OxyContin Action Plan, targeting the drug. Negative media coverage links OxyContin to heroin, fueling fear. The Orlando Sentinel publishes a flawed series on OxyContin overdoses, significantly contributing to fear.
- 2001: The US invades Afghanistan following the 9/11 attacks. Poppy cultivation is at a historic low due to a short-lived Taliban ban.
- Post-2001: The US, DEA, and CIA work with Afghan narco-warlords (part of the Northern Alliance). The US-backed Afghan government legalizes poppy cultivation. Afghanistan becomes the world’s largest opium producer. DEA FAST teams conduct military-style raids. The US implements compensated eradication and creates the Afghan Eradication Force (AEF/PEF). Aerial spraying is considered but opposed. The US-backed Afghan government is deeply involved in the drug trade. The US implements alternative livelihood programs with mixed results.
- 2002: The DEA reallocates resources to prescription drugs in rural areas, focusing on “illegal diversion” of legal medication. The DEA expands via task forces. The DEA justifies its OxyContin campaign with flawed data on “OxyContin-related deaths.”
- 2003: The DEA doubles licensing fees to fund the Diversion Control Program, making doctors financially responsible for investigating colleagues. The DEA uses threats to coerce patients to report doctors. A NADDI conference focuses on targeting pain specialists and asset seizure. Florida becomes restrictive on pain treatment due to the Sentinel series.
- 2004: The DEA disavows its guidance pamphlet for pain specialists, increasing doctors’ fear. Dr. William Hurwitz is convicted. Dr. Frank Fisher is acquitted after years of legal battles and asset seizures.
- 2004 (November 16): The DEA publishes an Interim Policy Statement, “Dispensing of Controlled Substances for the Treatment of Pain,” which emphasizes enforcement and seems likely to have a chilling effect on physicians. ***SEE COMPLETE DETAIL TIME IN BELOW REFERENCES
The text discusses a patented forensic system used to detect prescription fraud, highlighting potential conflicts of interest and questioning its scientific validity.
Finally, one source analyzes the unintended negative economic consequences of the Taliban’s opium ban in Afghanistan, while another provides context and study materials related to the accusations against Dr. King.

Briefing Document: Analysis of Sources on Biased Medical Experts and the Opioid Crisis
Date: March 15, 2025 (based on source publication date)
Subject: Review of Concerns Regarding Biased Medical Expert Testimony in Opioid-Related Cases and Related Contextual Information
Executive Summary:

This document presentation synthesizes information from three sources to highlight concerns regarding the role of biased medical experts in the prosecution of physicians during the opioid crisis, alongside related discussions on a patented forensic system used in these cases and the broader context of the opioid epidemic’s impact.
The sources collectively argue that some medical experts act as “hired guns,” providing flawed and biased testimony that leads to unjust legal actions against doctors. Furthermore, they critique the scientific basis of certain opioid prescribing guidelines and data analysis tools used in these prosecutions.
The briefing also touches upon the economic impact of the Taliban’s opium ban in Afghanistan as a seemingly disparate but relevant point on the complexities of opioid-related policies.
Source 1: Excerpts from “Pasted Text”: How biased medical experts are destroying doctors’ lives and careers in the opioid crisis by Richard A. Lawhern, PhD
Main Themes and Key Ideas:
- Allegations of Biased “Medical Experts”: Lawhern argues that many “medical experts” hired by prosecutors in cases against doctors are “hired guns” who provide biased testimony based on a superficial understanding of the medical literature. He believes these experts contribute to the “persecution” of physicians.
- Quote: “I believe that “medical experts” in many court or Medical Board proceedings are simply “hired guns” – clinical predators hired for large sums of money to tell stories whose details they do not themselves understand.”
- Lack of Understanding by Legal System and Media: The author contends that judges, juries, and journalists often lack the necessary understanding of medical literature and its weaknesses to assess the credibility of expert witnesses.
- Quote: “In my view, no judge or jury is competent to assess the credibility of a witness who testifies against a doctor unless both the witness and the judge understand not only the content of the medical literature but also its major weaknesses. Most judges and juries — and media reporters — understand even less.”
- Problems with Scientific Peer Review and the Replication Crisis: Lawhern highlights the failures within the peer review process in medical literature and the broader “replication crisis” in science, suggesting that even published studies can be flawed or biased.
- Quote: “However, we now know that the peer review process is failing in medical literature just as it is in psychology and psychiatry – and even physics. This failure is a dimension of what we call the “replication crisis,” and relatively few judges or journalists are even aware of the problem.”
- Impact on Pain Management Physicians: The article details the negative consequences for doctors who treat pain with opioids, including being targeted by law enforcement and medical boards, facing raids, and having their practices ruined due to allegations of improper prescribing.
- Quote: “For a doctor who treats pain with opioid pain relievers, these errors can result in profound miscarriages of justice. U.S. physicians have reported being targeted by drug enforcement agencies and medical boards for prescribing opioids, even when they have done so legitimately for chronic pain management.”
- Critique of Standard Opioid Prescribing Guidelines: Lawhern questions the existence of a universally accepted “consensus standard” for opioid prescribing and criticizes the CDC guidelines as being based on weak evidence and containing anti-opioid bias.
- Quote: “However uncomfortable this reality may be for medical boards, prosecutors, judges, or political decision-makers, there is presently no consensus standard by which a doctor’s prescribing practices can be determined to lie outside usual and accepted conditions of practice.”
- Questions for Medical Experts: The author proposes specific questions that should be posed to medical experts testifying against doctors, focusing on their practical experience, understanding of opioid dependence vs. addiction, and knowledge of pain management complexities.
- Opioids as “Innocent Bystanders”: Lawhern suggests that opioids themselves are not the primary cause of overdose deaths and that pre-existing conditions like suicidal ideation and psychiatric disorders are more significant risk factors.
- Quote: “In all probability, opioids are actually innocent bystanders in the causation of these tragedies.”
Source 2: Briefing Document: “THE GREAT KING RAT: UNCOVERING DOJ- DEA’s DR. TIMOTHY E. KING, MD TRAVELING SHOW OF LIES AND DECEPTIONS”
from youarewithinthenorms.com
Main Themes and Key Ideas:
- Accusations Against Dr. Timothy King: This source focuses on Dr. Timothy King, a physician frequently used as a government expert witness in opioid-related cases, labeling him the “RAT KING” and accusing him of providing false, biased, and misleading testimony.
- Quote: “Most definitively, Dr. Timothy King who has served as the foundational expert for United States Department of Justice (DOJ) and the Drug Enforcement Administration (D.E.A.) testimonies, is and has been defective and the conclusions generated and drawn from his analysis have been and are thus fraudulent.”

- Impact on Healthcare Professionals: The article argues that Dr. King’s testimony has led to the unjust prosecution, conviction, and suffering of numerous healthcare professionals, including physicians, pharmacists, and dentists.
- Quote: “King, a physician who has risen to notoriety as a government expert, has been accused of knowingly perpetuating a web of deception that has led to the unjust incarceration and devastation of countless innocent healthcare professionals.”
- Critique of “Objective Evidence” for Pain: The article challenges Dr. King’s insistence on “objective evidence” of functional improvement for legitimate opioid prescriptions, highlighting the subjective nature of pain.
- Quote: “One of the core contentions against Dr. King’s testimonies is his insistence on the need for “objective evidence” of functional improvement for legitimate opioid prescriptions. However, the nature of pain is subjective, making it challenging to quantify and assess it objectively.”
- Allegations of Prosecutorial Misconduct: The source suggests that prosecutors have misrepresented Dr. King’s testimony to strengthen their cases, potentially misleading juries.
- Quote: “The issue of prosecutorial misconduct came under scrutiny, with the prosecution allegedly misrepresenting Dr. King’s testimony to bolster their case.”
- Conflict of Interest Related to Patented System: The article points to a potential conflict of interest arising from Dr. King’s patented system for assessing opioid prescription writing, arguing that it incentivizes him to find more violations to increase his opportunities for government contracts and consulting work.
- Quote: “Dr. King’s patented system, used to determine whether healthcare providers violated controlled substances laws, allegedly creates a conflict of interest… This incentivizes him to target more providers, which in turn increases his opportunities for government contracts and insurance consulting work.”
- Debunking the “90 MME” Assertion: The article criticizes Dr. King’s stance that opioid prescriptions should never exceed 90 MME, noting the lack of scientific evidence for this absolute limit and its conflict with FDA and DEA policies.
- Quote: “Dr. King’s emphatic statement that opioids should never exceed 90 MME was challenged, as this absolute limit conflicts with existing FDA and DEA policies which do not support such an absolute limit.”
- Alleged Racketeering Scheme: The source claims that Dr. King is a key figure in a corrupt alliance involving for-profit healthcare insurance corporations and unscrupulous physicians to manipulate pain management practices for financial gain.
- Quote: “At the heart of this sordid tale lies a complex web of corruption involving for-profit healthcare insurance corporations and unscrupulous physicians who provide false expert testimony to further their personal ambitions.”

- Critique of Qlarant’s Data Analysis: The article questions the scientific basis of Qlarant’s data analytics, which are used to identify aberrant prescribing behavior, highlighting errors in PDMP data and the arbitrary nature of the 90 MME threshold.
- Quote: “QLARANT HAS NO SCIENTIFIC ORIGINS IN THEIR ANALYSIS… Patients who are prescribed more than 100 morphine equivalents per day ( there is no scientific origin of 90 MME maximum daily dose, nor any scientific evidence of it except it is an arbitrary number).”
- Impact on Patients: The alleged actions of Dr. King and the resulting crackdown on opioid prescribing are said to lead to patient abandonment, increased suffering, and even suicides.
- Quote: “The consequences have severe, including unjust incarceration, loss of medical licenses, financial devastation for healthcare professionals, and a chilling effect on legitimate pain management practices. This has lead to patient abandonment, where patients are left without adequate care, potentially causing increased suffering, decreased quality of life, and, in some many cases, suicide.”
- Reference to “Neo-Eugenics”: The article includes a statement linking the DOJ’s approach to opioid prescribing, potentially influenced by figures like Dr. King and Dr. Kolodny, to “eugenics or Neo-Eugenics.”
- Quote: “Think about it, People…On Kolodny and Prop…, the DOJ has adopted eugenics or Neo-Eugenics. As David SteinMD put it, they’ve resurrected and repackaged the old eugenic philosophy so that history doesn’t repeat itself, but it, sure enough, rhymes.”
Source 3: Briefing Document From: Forensic System and Method for Detecting Fraud, Abuse, and Diversion in Controlled Substance Prescriptions (Excerpts from Dr. King’s Fraudulent U.S. Patent Application Publication US 2020/0143925 A1)
Main Themes and Key Ideas:
- Description of a Forensic System: This document outlines a patented system and method for analyzing medical and pharmacy data to detect fraud, abuse, and diversion in controlled substance prescriptions. The inventor is identified as Timothy Earl King.
- Quote: “The present invention relates to a forensic system and method… for analyzing medical and pharmacy data to determine the legitimacy of controlled substance prescription and use, and to detect fraud, abuse, and/or diversion of controlled substances.”
- Objective Data for Legal Evaluation: The system aims to provide objective, data-based evidence to determine the legitimacy of prescriptions, intending to overcome the limitations of subjective expert opinions in legal proceedings.
- Quote: “In one aspect, said method provides objective evidentiary data that shows with high certainty whether a suspected medical practitioner has been issuing controlled substance prescriptions ‘outside the usual course of medical practice’ and/or ‘for other than legitimate medical purposes’.”
- Three Sequential Work Products: The methodology involves generating three spreadsheet-based documents:
- Forensic Chronology: Integrates patient medical records and PDMP data into a chronological timeline.

- Quote: “Said method rearranges, orga-nizes, and simplifies the complex data in patients’ medical and PDMP charts, and provides a series of three sequential work products in spreadsheet form, a Forensic Chronology chart, a Forensic Summary chart, and a Standard of Care Summary chart…”
- Forensic Summary: Summarizes data from multiple Forensic Chronology charts based on criteria for legitimate controlled substance use.
- Quote: “It comprises a succinct summarization of relevant data that is gleaned from the patients’ Forensic Chronology documents… It is likewise presented in spreadsheet format, so as to facilitate review and interpretation, via which a medical-legal opinion can be derived.”
- Standard of Care Summary: A one-page summary rating compliance with standards of care using a notation system.
- Quote: “It is typically a one-page product that comprises a concise spreadsheet summary of the Forensic Summary described above, expressed as a series of notations representing whether parameters…listed under the Standards of Care have been legally fulfilled.”
- Intended Use in Legal Proceedings: The system is designed for use by legal scholars, prosecutors, defense attorneys, and juries to help them make legal conclusions about potential fraud, abuse, or diversion of controlled substances.
- Quote: “…medical data is effectively trans-lated into objective criteria from which a legal conclusion can be determined by legal scholars, prosecutors, defense attorneys, and juries.”
- Reference to DEA Guidelines: The application references the DEA Practitioner’s Manual and the Controlled Substances Act (CSA), emphasizing adherence to the “usual course of professional medical practice” and the need for scientifically valid methodologies.
- Quote: “The Practitioner’s Manual defines the key parameters within which controlled substances are to be prescribed, and stipulates that, for a prescription for a controlled substance to be valid, the prescription must be issued for a legitimate medical purpose by a practitioner acting in the usual course of professional practice.”
- Inventor’s Expertise: Timothy Earl King is presented as a highly qualified medical expert with experience in anesthesiology, pain management, and addiction, who has worked with law enforcement agencies.
Connecting the Sources:
The three sources present a clear conflict and offer different perspectives on the opioid crisis and the legal actions against prescribing physicians. Lawhern and the “Great King Rat” article express strong concerns about biased medical experts, particularly focusing on Dr. Timothy King and his methods.
They argue that these experts, along with flawed prescribing guidelines and data analysis tools like Qlarant’s, contribute to the unjust prosecution of doctors and harm to patient chronically ill suffering pain.



The patent application, on the other hand, describes Dr. King’s “Forensic System” as an objective, data-driven tool to identify illegitimate prescribing practices.
This directly contradicts the claims in the other sources that Dr. King’s methodologies are biased, flawed, and used to persecute innocent healthcare professionals. The “Great King Rat” article specifically targets this patented system as a source of conflict of interest and a tool used to generate biased testimony.

While seemingly unrelated, William Byrd’s analysis of the Taliban’s opium ban in Afghanistan highlights the complex and unintended consequences of policies aimed at curbing opioid production.
This serves as a broader reminder of the multifaceted nature of opioid-related issues and the potential for well-intentioned interventions to have negative impacts.

Conclusion:
The provided sources raise significant concerns about the role of medical expert testimony in opioid-related legal cases, particularly regarding allegations of bias and conflicts of interest.
The debate surrounding Dr. Timothy King and his patented forensic system underscores the tension between the need for objective methods to combat prescription drug abuse and the potential for such methods to be misused or based on flawed assumptions, leading to unjust outcomes for healthcare professionals.
The broader context of the opioid crisis, as touched upon by the discussion of the Taliban’s opium ban, emphasizes the complexity of addressing opioid-related issues and the need for careful consideration of unintended consequences.



CRIMINAL DEFENSE ATTORNEYS
The concept of “pre-crime,” once confined to the realm of science fiction as depicted in the film “Minority Report,” has evolved into a modern-day reality with the use of “risk assessments” in contemporary law enforcement. This transformation raises significant concerns about civil liberties, racial bias, and the erosion of constitutional protections.


Paul J Hetznecker Esq.
Federal public defenders Paul J. Hetznecker and Coley O. Reynolds are delving into this issue as they examine its relevance in the ongoing case of United States v. Anand. “Pre-crime” is the notion of predicting and preventing crimes before they occur, relying on computer-based risk assessments that profile individualsbased on data-driven algorithms. Hetznecker’s article highlights the transformation of “pre-crime” from a dystopian idea to a contemporary practice, where law enforcement uses “risk assessments” to predict future criminal behavior.
In an article published on September 12, 2016, titled “Pre-Crime” and the Danger of “Risk Assessments” by Paul J. Hetznecker, the author provides valuable insights into the concept of “pre-crime” and its impact on the criminal justice system.
The primary narrative driving policy is that the opioid epidemic is driven by overprescribing by clinicians, leading patients to become addicted. This has led to draconian laws that have harmed chronic pain patients and the use of invasive prescription monitoring programs throughout the country.

Dr. CATHLEEN LONDON ,MD, Esq
“The blame for that falls on the DEA (Drug Enforcement Agency), Congress, and lobbyists. This focus on limiting the prescribing of legal opioids has led to an increasingly lethal illicit opiate supply. The DOJ continues to erroneously cite diversion of licit legitimate prescriptions of opioids as the problem...” Dr. CATHLEEN LONDON ,MD, Esq

” The black box algorithms mine data and have never been subjected to independent verification. Patients and prescribers alike are flagged as problematic. Although prescribing has dropped dramatically since the introduction of prescription monitoring, overdose deaths have risen dramatically to record highs, driven by the illicit fentanyl market.
Despite this, law enforcement continues to focus on the diversion of prescription medication. The drug prohibition policy set out by the Department of Justice (DOJ) is a misguided attempt to address skyrocketing opioid overdoses. It is their way of trying to fix the issue which was the unchecked distribution of opioids.

The blame for that falls on the DEA (Drug Enforcement Agency), Congress, and lobbyists. This focus on limiting the prescribing of legal opioids has led to an increasingly lethal illicit opiate supply. The DOJ continues to erroneously cite diversion of licit legitimate prescriptions of opioids as the problem.
As a result, doctors have been imprisoned for terms ranging from twenty years to life without parole, all for practicing medicine. Others have had their careers and reputations irreparably harmed.

Under treated pain is an expensive medical condition, costing an estimated $560-635 billion annually in the United States.
With the current climate of fear and prohibition, and the government’s decision to prosecute doctors who they claim overprescribe, we are in a cycle that started with the Harrison Act in 1914. Drafted as tax law, the Harrison Act required anyone authorized to manufacture or distribute narcotics to register with the Treasury Department, pay a fee and keep records.”
OR SEND
TO CASH APP:$docnorm
ZELLE 3135103378

ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!

FOR NOW, YOU ARE WITHIN
THE NORMS

REFERENCES:
Opioid Regulation and Enforcement: A Timeline and Key Figures
Detailed Timeline of Main Events:
Late 19th Century (Progressive Era)
1880s-1920: Narcotics are unregulated and widely available in the United States.
1914: The Harrison Act criminalizes the non-medical use of opium, morphine, and cocaine, effectively turning drug-addicted citizens and their doctors into criminals.
1914-1938: Approximately 25,000 doctors are arrested under the Harrison Act for prescribing narcotics to addicts. Public opinion turns against doctors.
1919: A Washington Times article highlights that narcotic drug use among the “better class of people” originated largely from physician prescriptions for pain relief.
1970: The Harrison Act is repealed and replaced with the Drug Abuse Prevention and Control Act (DAPCA).


2000s
1999-2001: Congress criticizes the DEA for a lack of progress against illegal drugs. The DOJ rebukes the DEA’s strategy, prompting a search for a new “front” in the War on Drugs.
Early 2000s: Opioid prescriptions skyrocket, increasing addiction. “Pill mills” emerge.
Early 2000s: Glen A. Fine, Inspector General of the Department of Justice, questions why the DEA isn’t doing more to combat prescription drug abuse.
2001: The DEA launches the OxyContin Action Plan, targeting the drug. Negative media coverage links OxyContin to heroin, fueling fear. The Orlando Sentinel publishes a flawed series on OxyContin overdoses, significantly contributing to fear.
2001: The US invades Afghanistan following the 9/11 attacks. Poppy cultivation is at a historic low due to a short-lived Taliban ban.
Post-2001: The US, DEA, and CIA work with Afghan narco-warlords (part of the Northern Alliance). The US-backed Afghan government legalizes poppy cultivation. Afghanistan becomes the world’s largest opium producer. DEA FAST teams conduct military-style raids. The US implements compensated eradication and creates the Afghan Eradication Force (AEF/PEF). Aerial spraying is considered but opposed. The US-backed Afghan government is deeply involved in the drug trade. The US implements alternative livelihood programs with mixed results.
2002: The DEA reallocates resources to prescription drugs in rural areas, focusing on “illegal diversion” of legal medication. The DEA expands via task forces. The DEA justifies its OxyContin campaign with flawed data on “OxyContin-related deaths.”
2003: The DEA doubles licensing fees to fund the Diversion Control Program, making doctors financially responsible for investigating colleagues. The DEA uses threats to coerce patients to report doctors. A NADDI conference focuses on targeting pain specialists and asset seizure. Florida becomes restrictive on pain treatment due to the Sentinel series.
2004: The DEA disavows its guidance pamphlet for pain specialists, increasing doctors’ fear. Dr. William Hurwitz is convicted. Dr. Frank Fisher is acquitted after years of legal battles and asset seizures.
2004 (November 16): The DEA publishes an Interim Policy Statement, “Dispensing of Controlled Substances for the Treatment of Pain,” which emphasizes enforcement and seems likely to have a chilling effect on physicians.
2005: The National Association of Attorneys General expresses concern to the DEA about its aggressive pursuit of physicians. Media continues to fuel OxyContin fears despite other sources of illicit drugs. The DEA establishes the Distributor Initiative Program. Joe Rannazzisi becomes director of the DEA’s Office of Diversion Control.
2005-2009: Diversion of millions of hydrocodone units is facilitated by rogue internet pharmacies and prescribers.
2005-2015: Under Joe Rannazzisi’s leadership, the number of registrants allowed to prescribe/dispense opioids grows by 45%, and quotas for hydrocodone and oxycodone significantly increase.

Around 2008: The DEA starts focusing on drug distributors. Heroin seizures at the Southwest border increase significantly from 2008 to 2013. The NSC establishes the Afghan Threat Finance Cell (ATFC) in Kabul, led by the DEA, to disrupt financial networks related to terrorism, the Taliban, narcotics trafficking, and corruption.
2009: Florida becomes a major hub for oxycodone distribution, accounting for 44% of all 30mg oxycodone tablets dispensed in the US.
Post-Ryan Haight Act: “Pain and wellness clinics” proliferate, particularly in Florida, following crackdowns on internet pharmacies.
Early 2010s: Law enforcement efforts target Florida pill mills, leading to a decrease in the state’s share of oxycodone 30mg distribution.
2010: Dr. Terence Sasaki is indicted for conspiracy to distribute controlled substances and launder money, allegedly based on a 2007 interrogation the DEA claimed was unrecorded regarding a 2005 crime.

2010-2011: An increase in DEA and DOD alignment in Afghanistan leads to a jump in interdiction operations.
2012: Dr. Terence Sasaki is convicted. International interest and investment in Afghan counternarcotics efforts begin to wane after this year.
2013: The UK all but abandons its involvement in eradication planning and counternarcotics policy in Afghanistan.
2013-2016: A period of neglect for counternarcotics in US policy towards Afghanistan.
Pre-2013: DEA begins scrutiny of Miami-Luken, a Dayton, Ohio pharmaceutical wholesaler.
2013: Wheatland Pharmacy case sets a precedent regarding the DEA’s obligation to conduct thorough investigations.

April 29, 2014: Deputy Assistant Administrator Joseph T. Rannazzisi of the DEA testifies before the House Energy and Commerce Subcommittee on Oversight and Investigations, addressing the growing problems of prescription drug and heroin abuse.
2015: DEA finds it increasingly difficult to mount interdiction operations in Afghanistan due to a reduced staff presence outside Kabul. Seizures of opium fall to their lowest levels since 2008.
March 2016: The “Marino bill” passes the Senate and House by unanimous consent and is signed into law by President Barack Obama without ceremony.
Post-Passage (2016): Drug distributors declare victory regarding the “Marino bill.” DEA Chief Administrative Law Judge John J. Mulrooney writes the law would make prosecuting distributors “all but…impossible.”
2017: Poppy cultivation in Afghanistan is estimated to provide up to 590,000 full-time-equivalent jobs.
June 2018: SIGAR report highlights that interdiction and counterdrug law enforcement programs in Afghanistan had tactical successes but failed strategically.
August 29, 2019: DEA agents raid Pronto Pharmacy in Tampa, Florida.
2019: James Barclay, an executive at Miami-Luken, is indicted.
November 4, 2019: DEA Deputy Assistant Administrator Thomas W. Prevoznik writes to Kevin Nicholson (NACDS), clarifying the DEA’s limited authority in regulating medical practice and prescription limits.
May 7, 2020: Publication date of the patent application (US 2020/0143925 A1) for Dr. Timothy King’s forensic system for detecting fraud in controlled substance prescriptions.
October 26, 2023: Publication date implied for the “THE GREAT KING RAT: UNCOVERING DOJ- DEA’s DR. TIMOTHY E. KING, MD TRAVELING SHOW OF LIES AND DECEPTIONS” briefing document.
February 12, 2021: Thomas W. Prevoznik writes to Richard A. Lawhern, explaining that the DEA does not define “legitimate medical purpose” or set medical practice standards.
2021: Prosecutors drop all charges against James Barclay and others related to Miami-Luken.
2021: DEA issues a Decision and Order regarding Pronto Pharmacy, finding no evidence of actual drug diversion and no proof of knowingly filling illegitimate prescriptions.
December 18, 2021: DEA writes a letter to Congresswoman Grace Meng, stating that the DEA is not in a position to authorize or dictate what a doctor prescribes.
August 3, 2022: Suntree Pharmacy files a Petition for a Writ of Certiorari to the Supreme Court, challenging the DEA’s interpretation of regulations.

September 6, 2022: Walmart publishes a statement correcting the record on opioid lawsuits, highlighting contradictory guidance from federal agencies.
September 24, 2022: “PAIN AND THE RULES OF LAW – youarewithinthenorms” article is published, detailing events surrounding Pronto Pharmacy, James Barclay, and Suntree Pharmacy, arguing DEA overreach.
Unknown Date: DEA conducts an administrative hearing for Suntree Pharmacy, relying on the testimony of Dr. Gordon.
Cast of Characters:
Key Individuals in Opioid Regulation and Enforcement:
Joe Rannazzisi: Former Director of the DEA’s Office of Diversion Control. Led a decade-long campaign of aggressive enforcement until forced out in 2015. Testified in 2014 on the connection between prescription opioid misuse and heroin use, and later presented on the history and issues of the opioid epidemic, emphasizing failures in the regulatory system.
Timothy Earl King, MD: Referred to as the “RAT KING.” A medical expert who has frequently testified for the prosecution in opioid-related cases, particularly in the Eastern District. Developed a patented “forensic system” for assessing opioid prescription writing, which critics argue creates conflicts of interest. Accused of biased and misleading testimony, misrepresenting studies, and relying on flawed science.
Thomas W. Prevoznik: DEA Deputy Assistant Administrator, Diversion Control Division. Author of letters clarifying the DEA’s position on prescribing controlled substances for pain, emphasizing the DEA’s limited authority in dictating medical practice or defining legitimate medical purpose, which rests with individual practitioners.
Asa Hutchinson: DEA administrator during the launch of the OxyContin Action Plan in 2001. Played a key role in framing OxyContin as dangerous.
John J. Mulrooney: DEA Chief Administrative Law Judge who stated that the “Marino bill” would make prosecuting drug distributors “all but…impossible.”
Jonathan Novak: Former DEA attorney who prosecuted opioid diversion cases. Believes the “Marino bill” made holding large distributors accountable nearly impossible.
Jim Geldhof: A 40-year DEA veteran who ran pharmaceutical investigations. Corroborates claims about drug distributors’ negligence.
Frank Younker: DEA supervisor who echoed frustration regarding the pharmaceutical industry’s actions and enforcement restrictions.
Healthcare Professionals Involved or Mentioned:
Norman J. Clement RPH., DDS: Pharmacist and owner of Pronto Pharmacy in Tampa, Florida, which was raided by the DEA in 2019.
Dr. Donald Sullivan: Professor at the Ohio State University College of Pharmacy. Served as a DEA consultant in the Pronto Pharmacy case.
Dr. Gordon: Clinical hospice pharmacist working from home as a consultant for ProCare RX. Testified for the DEA in the administrative hearing for Suntree Pharmacy, identifying “red flags.”
Dr. William Hurwitz: Physician convicted in 2004 despite no evidence of malicious intent, seen by some as an example of DEA overreach.
Dr. Frank Fisher: Physician acquitted in 2004 after years of legal battles and asset seizures, another case highlighting the risks faced by doctors prescribing opioids.
Dr. Terence Sasaki, MD: Neurologist convicted in 2012 of conspiracy to distribute controlled substances and launder money based on controversial circumstances.
Dr. Jay K. Joshi, MD, MBA: Physician, author of “Burden of Pain,” presenting a perspective on the opioid epidemic.
Dr. Andrew Kolodny, MD: Mentioned in an advertisement suggesting a link between his work and “eugenics” or “Neo-Eugenics.”
David Stein,MD: Quoted in an advertisement, drawing a parallel between DOJ policies related to opioid prescribing and eugenics.

Naburun Dasgupta, PhD: Co-author of “Opioids ‘No Easy Fix’ University of North Carolina,” whose expertise is cited in questioning Dr. King’s methodologies and reliance on MME.
Robert Curtis: Individual quoted as believing Dr. King belongs in prison and calling for the arrest of top DEA and DOJ officials involved in physicians’ convictions.
Dr. L. Joseph Parker, MD: Physician with a background in science and space exploration, mentioned in an advertisement.
Neail Anand, MD: Physician mentioned as having been aggressively prosecuted for his medical practice.
Dr. Russell K. Portenoy: Pain specialist who criticized the DEA’s actions.
Dr. John F. Lilly, Dr. James Graves, Dr. Sarfraz Mirza, Dr. Asuncion Luyao, Dr. Eli Schneider, Dr. Ghassan Haj-Hamed: Other doctors mentioned in the context of the DEA’s crackdown on prescription painkillers (from the Cato Institute paper).
Government and Legal Figures:
Glen A. Fine: Inspector General of the Department of Justice in the early 2000s, questioned the DEA’s efforts against prescription drug abuse.
Eric Holder: Former Attorney General of the United States who warned against the “Marino bill.”
Tom Marino: Former Republican Congressman who co-sponsored the legislation weakening the DEA’s enforcement powers (“Marino bill”).
President Barack Obama: Signed the “Marino bill” into law.
U.S. Department of Justice (DOJ): The federal department overseeing the DEA, whose policies and actions are central to the narrative.
Honorable James McFarland: Judge presiding over the James Barclay case.
Individuals and Entities Related to Pharmaceutical Distribution and Regulation:
James Barclay: Executive at Miami-Luken, a pharmaceutical wholesaler investigated by the DEA.
Miami-Luken: A pharmaceutical wholesaler in Dayton, Ohio, scrutinized by the DEA for alleged diversion.
National Association of Chain Drug Stores (NACDS): Received clarification from the DEA regarding their authority in medical practice.
Walmart: Published a statement correcting the record on opioid lawsuits and highlighting contradictory guidance received by pharmacists.
Qlarant: A company advertising analytic tools to measure aberrant behavior in opioid prescribing, whose methodology is criticized in relation to Dr. King’s work and the subjectivity of opioid equivalencies.
Afghanistan and International Context:
William Byrd, Ph.D.: Development economist and senior expert on Afghanistan, analyzed the economic consequences of the Taliban’s opium production ban and US counternarcotics efforts.
Zabihullah Mujahid: Taliban spokesman.
Fahim Khan: Major Afghan warlord and narcotics trafficker within the US-backed Afghan government.

Ahmed Wali Karzai: Major Afghan warlord and narcotics trafficker within the US-backed Afghan government.
Gulbuddin Hekmatyar: Afghan warlord and drug trafficker who received significant DEA support during the Soviet occupation.
Admiral Thrasher (Implied): Likely the head of the International Narcotics Control Board (INCB), whose report highlighted high US opioid consumption.
Other Notable Individuals:
Ronald T. Libby: Author of a 2005 Cato Institute report criticizing the DEA for overreaching its authority and contributing to the undertreatment of pain.
Ryan Haight: The namesake of the Ryan Haight Online Pharmacy Consumer Protection Act.
Justice Thurgood Marshall: US Supreme Court Justice who questioned the limits of a doctor’s authority to prescribe controlled substances in United States v. Moore.
Moore: The physician involved in the United States v. Moore case.
Siegfried (Implied): Likely refers to a method or chemist associated with fentanyl synthesis.
Richard A. Lawhern, Ph.D.: Patient advocate who received clarification from the DEA regarding their role in medical practice.

Leo Beletsky: Professor at Northeastern University School of Law, criticizes DEA’s tactics for targeting prescribers.
Thomas Sydenham: 17th-century English physician who popularized laudanum.
Unidentified Individual (1500s): Mentioned as starting an early form of laudanum.
John Newman: Professor who introduced Joe Rannazzisi at a presentation.
Tommy Farmer: Colleague of Joe Rannazzisi who presented on similar topics.
This timeline and cast of characters provide a detailed overview of the main events and individuals discussed within the provided sources, highlighting the complexities and controversies surrounding opioid regulation, enforcement, and the impact on healthcare professionals and patients.

Understanding the Opioid Crisis and the Role of Dr. Timothy King
Quiz
- According to the provided text, what are some reasons why patients with severe chronic pain might face higher mortality rates? Are these factors attributed to the use of FDA-approved opioid pain relievers?
- What is the definition of “opioid dependence” as described in the text? How does it differ from the concept of “pseudo-addiction” (even though the definition of the latter isn’t provided in this excerpt)?
- What are the main allegations made against Dr. Timothy King, often referred to as the “RAT KING,” in the advertisements and articles presented?
- What is Dr. King’s patented system designed to do, and what potential conflict of interest is associated with it according to the text?
- How is Dr. King’s expertise challenged in the text, particularly regarding his use of studies and reliance on morphine milligram equivalents (MME)?
- What did the CDC state regarding the 90 MME maximum daily dose recommendation, and how should it not be used by law enforcement?
- What was the focus of the research paper analyzing oxycodone impurities, and how did its findings allegedly undermine Dr. King’s methodologies and Qlarant’s database?
- According to the patent application for Dr. King’s “forensic system,” what is the intended purpose of this system and the three “work products” it generates?
- Based on the provided “Cast of Characters,” what were some of the roles and areas of expertise of Timothy Earl King?
- According to the “FAQ: Pain and the Rule of Law” section, what is the central issue raised regarding the DEA’s involvement in pain management, and what is one criticism of the DEA’s use of “red flags”?
Answer Key
- Patients with severe chronic pain often face higher mortality rates due to underlying conditions such as cancer, diseases of the circulatory and respiratory systems, and suicide. The text explicitly states that none of these factors are a consequence of the use of prescription opioid drugs approved by the U.S. FDA.
- Opioid dependence in medical practice is described as a purely physical reaction where patients treated with opioid pain relievers may experience withdrawal symptoms if their medication is tapered too rapidly. While “pseudo-addiction” isn’t defined here, the distinction suggests opioid dependence is a physiological response, not necessarily the psychological and behavioral patterns associated with addiction.
- The main allegations against Dr. Timothy King include being a serial liar, maliciously targeting healthcare professionals leading to unjust prosecutions, providing biased testimony based on flawed science, and having conflicts of interest due to his patented system for assessing opioid prescriptions.
- Dr. King’s patented system is designed to determine whether a healthcare provider violated controlled substances laws. A potential conflict of interest is alleged because the system incentivizes him to target more providers, increasing his opportunities for government contracts and insurance consulting work.
- Dr. King’s expertise is challenged through accusations of misrepresenting evidence from cited studies and his reliance on MME, which is critiqued for lacking scientific rigor and failing to account for individual patient variability.
- The CDC stated that the 90 MME maximum daily dose is a recommendation and should not be used by law enforcement to attack physicians who prescribe more based on a patient’s individual needs.
- The research paper investigated the presence of hydrocodone and hydromorphone in urine drug tests of patients prescribed only oxycodone to determine if the ratio of these substances could differentiate legitimate use from other opiate use. The findings of detectable impurities allegedly expose Qlarant’s database as fraudulent and invalidate Dr. King’s patent and methodologies.
- The intended purpose of the forensic system is to provide objective, data-based evidence to determine the legitimacy of controlled substance prescriptions and to detect fraud, abuse, and/or diversion. The three work products (Forensic Chronology, Forensic Summary, and Standard of Care Summary) translate complex medical data into objective criteria for legal evaluation.
- Timothy Earl King is described as a medical doctor with expertise in anesthesiology, pain management, and addiction. He is the applicant and inventor of the forensic system and method and has a history of working with law enforcement and regulatory agencies like the DEA and DOJ.
- The central issue raised is the DEA’s alleged overreach and misinterpretation of the Controlled Substances Act, acting as a rogue agency that creates its own medical guidelines and criminalizes legitimate medical practices. One criticism of the DEA’s use of “red flags” is that they often lack context and fail to consider individual patient circumstances or the complexities of pain management, yet are used to justify investigations.

Essay Format Questions
- Critically analyze the role of Dr. Timothy King as presented in the provided sources. Consider the accusations against him, his patented system, and the arguments regarding his influence on opioid-related prosecutions. To what extent do the sources provide convincing evidence of his alleged misconduct and its impact on the judicial system?
- Evaluate the arguments made in the text regarding the Drug Enforcement Administration’s (DEA) approach to regulating opioid prescriptions. Consider the criticisms of their tactics, their authority in defining “legitimate medical purpose,” and the alleged consequences of their enforcement actions on both healthcare professionals and patients.
- Discuss the concept of “objective evidence” versus clinical judgment in the context of opioid prescribing, as highlighted in the criticisms of Dr. King’s methodologies. What are the challenges in determining the legitimacy of pain treatment, and how should legal and medical perspectives balance quantitative data with individual patient needs and experiences?
- Analyze the potential conflicts of interest identified in the provided materials, such as Dr. King’s patented system and the movement of individuals between government agencies (like the DEA) and the pharmaceutical industry. How might these conflicts impact the regulation and prosecution of opioid-related cases, and what measures could be implemented to mitigate such issues?
- Based on the various perspectives presented, what appears to be the central conflict or tension surrounding the opioid crisis and its legal ramifications for healthcare professionals? Consider the roles of law enforcement, medical practitioners, regulatory bodies, and the concept of “legitimate medical purpose” in this complex issue.
Glossary of Key Terms
Patent: A government authority granting exclusive rights for an invention, which allows the patent holder to exclude others from making, using, or selling the invention for a set period.
Opioid Dependence: A physiological state of adaptation to chronic opioid exposure, characterized by withdrawal symptoms upon abrupt discontinuation or rapid dose reduction.
Pseudo-Addiction: A term used to describe drug-seeking behavior by pain patients that resembles addiction but is actually driven by undertreated pain. The behavior ceases when adequate pain relief is provided.
Morphine Milligram Equivalent (MME): A standardized unit used to express the potency of different opioid medications relative to morphine. It is used to assess the total opioid dose a patient is receiving.
Diversion: The process by which legally manufactured controlled substances are channeled into illicit markets or used for non-medical purposes.
Pill Mill: An informal term for a healthcare practice, often a pain clinic, that prescribes opioid medications indiscriminately and without legitimate medical necessity.
DEA (Drug Enforcement Administration): The federal law enforcement agency under the U.S. Department of Justice responsible for enforcing the controlled substances laws and regulations of the United States.
DOJ (Department of Justice): The federal executive department responsible for the enforcement of the law and administration of justice in the United States, overseeing the DEA.
Forensic System: In this context, refers to Dr. King’s patented methodology for analyzing medical and pharmacy data to detect potential fraud, abuse, and diversion in controlled substance prescriptions.

Red Flags: Indicators or patterns in prescribing or patient behavior that law enforcement or regulatory agencies may consider suspicious and potentially indicative of drug diversion or misuse.
Legitimate Medical Purpose: The standard required for a prescription of a controlled substance to be valid, meaning it must be issued for a genuine medical need by a practitioner acting in the usual course of professional practice.
Eugenics/Neo-Eugenics: A set of beliefs and practices that aim to improve the genetic quality of the human population, historically often involving discriminatory and coercive measures. In the context of the text, it’s used metaphorically to suggest a discriminatory approach by the DOJ towards certain groups (prescribers).
Subject Matter Expert (SME): An individual who has extensive knowledge and expertise in a particular field, often called upon to provide testimony or opinions in legal proceedings.
Conflict of Interest: A situation in which a person or organization is involved in multiple interests, financial or otherwise, one of which could potentially corrupt the motivation or decision-making of the individual or organization.